Would [ADXS] not they need a pre-clinical dataset for a specific PD-1/PDL-1?
Pre-clinical data in support of the HOT IND with one of the FDA-approved checkpoint inhibitors probably suffices for a phase-1 study with any of the four FDA-approved checkpoint inhibitors because the checkpoint inhibitors are so similar to each other.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”